Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9

References

• CatapanoALGrahamIDe BackerG2016 ESC/EAS guidelines for the management of dyslipidaemiasEur Heart J2016372999305827567407
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCCiceroAFA nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidenceAtheroscler Suppl20172411527998714
   PubMed Web of Science ®Google Scholar
• SahebkarASerbanMCGluba-BrzozkaALipid-modifying effects of nutraceuticals: an evidence-based approachNutrition2016321179119227324061
   PubMed Web of Science ®Google Scholar
• AnastasiusMKockxMJessupWSullivanDRyeKAKritharidesLCholesterol efflux capacity: an introduction for cliniciansAm Heart J2016180546327659883
   PubMed Web of Science ®Google Scholar
• KheraAVCuchelMde la Llera-MoyaMCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosisN Engl J Med201136412713521226578
   PubMed Web of Science ®Google Scholar
• RohatgiAKheraABerryJDHDL cholesterol efflux capacity and incident cardiovascular eventsN Engl J Med20143712383239325404125
   PubMed Web of Science ®Google Scholar
• SaleheenDScottRJavadSAssociation of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control studyLancet Diabetes Endocrinol2015350751326025389
   PubMed Web of Science ®Google Scholar
• ModyPJoshiPHKheraAAyersCRRohatgiABeyond coronary calcification, family history, and C-reactive protein: cholesterol efflux capacity and cardiovascular risk predictionJ Am Coll Cardiol2016672480248727230043
   PubMed Web of Science ®Google Scholar
• WeibelGLDrazul-SchraderDShiversDKImportance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosisArterioscler Thromb Vasc Biol201434172524202308
   PubMed Web of Science ®Google Scholar
• AdorniMPZimettiFPuntoniMCellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresisJ Lipid Res20125398498922414482
   PubMed Web of Science ®Google Scholar
• RondaNGrecoDAdorniMPNewly identified antiathero-sclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolismArthritis Rheumatol20156751155116425605003
   PubMed Web of Science ®Google Scholar
• NorataGDTavoriHPirilloAFazioSCatapanoALBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol loweringCardiovasc Res201611242944227496869
   PubMed Web of Science ®Google Scholar
• FerriNMarchianoSTibollaGPCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placementAtherosclerosis201625321422427477186
   PubMed Web of Science ®Google Scholar
• LeanderKMalarstigAVan’t HooftFMCirculating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factorsCirculation20161331230123926896437
   PubMed Web of Science ®Google Scholar
• XieWLiuJWangWAssociation between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort studyInt J Cardiol201621529329827128549
   PubMed Web of Science ®Google Scholar
• RuscicaMFerriNFogacciFCirculating levels of proprotein convertase subtilisin/kexin type 9 and arterial stiffness in a large population sample: data from the Brisighella Heart StudyJ Am Heart Assoc Epub201753
   Web of Science ®Google Scholar
• AdorniMPCipollariEFavariEInhibitory effect of PCSK9 on ABCA1 protein expression and cholesterol efflux in macrophagesAtherosclerosis20172561627940374
   PubMed Web of Science ®Google Scholar
• FeigJEHewingBSmithJDHazenSLFisherEAHigh-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studiesCirc Res201411420521324385513
   PubMed Web of Science ®Google Scholar
• RizzoMBerneisKKoulourisSShould we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?Int J Clin Pract2010641632164220831734
   PubMed Web of Science ®Google Scholar
• RichardCCouturePDesrochesSEffect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndromeBr J Nutr201210770571121787450
   PubMed Web of Science ®Google Scholar
• PuSRodriguez-PerezCRamprasathVRSegura-CarreteroAJonesPJDietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: a randomized control trialVascul Pharmacol201687606527374222
   PubMed Web of Science ®Google Scholar
• ZhuYHuangXZhangYAnthocyanin supplementation improves HDL-associated paraoxonase 1 activity and enhances cholesterol efflux capacity in subjects with hypercholesterolemiaJ Clin Endocrinol Metab20149956156924285687
   PubMed Web of Science ®Google Scholar
• BadeauRJauhiainenMMetsoJEffect of isolated isoflavone supplementation on ABCA1-dependent cholesterol efflux potential in postmenopausal womenMenopause20071429329917224860
   PubMed Web of Science ®Google Scholar
• MomtaziAABanachMPirroMKatsikiNSahebkarARegulation of PCSK9 by nutraceuticalsPharmacol Res201712015716928363723
   PubMed Web of Science ®Google Scholar
• TrimarcoVIzzoRStabileEEffects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endothelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trialHigh Blood Press Cardiovasc Prev20152214915425870124
   PubMedGoogle Scholar
• KhalilHMurrinCO’ReillyMTotal HDL cholesterol efflux capacity in healthy children – associations with adiposity and dietary intakes of mother and childNutr Metab Cardiovasc Dis201727707727919542
   PubMed Web of Science ®Google Scholar
• FavariERondaNAdorniMPABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjectsJ Lipid Res20135423824323103472
   PubMed Web of Science ®Google Scholar
• PisciottaLFavariEMagnoloLCharacterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3Circ Cardiovasc Genet20125425022062970
   PubMedGoogle Scholar
• MarkwellMAHaasSMBieberLLTolbertNEA modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samplesAnal Biochem19788720621098070
   PubMed Web of Science ®Google Scholar
• RuscicaMFerriNMacchiCLiver fat accumulation is associated with circulating PCSK9Ann Med20164838439127222915
   PubMed Web of Science ®Google Scholar
• VarboANordestgaardBGRemnant lipoproteinsCurr Opin Lipidol20172830030728548974
   PubMed Web of Science ®Google Scholar
• ZimettiFWeibelGKDuongMRothblatGHMeasurement of cholesterol bidirectional flux between cells and lipoproteinsJ Lipid Res20064760561316327021
   PubMed Web of Science ®Google Scholar
• YamamotoSNaritaIKotaniKThe macrophage and its related cholesterol efflux as a HDL function index in atherosclerosisClin Chim Acta201645711712227087419
   PubMed Web of Science ®Google Scholar
• HernaezAFernandez-CastillejoSFarrasMOlive oil poly-phenols enhance high-density lipoprotein function in humans: a randomized controlled trialArterioscler Thromb Vasc Biol2014342115211925060792
   PubMed Web of Science ®Google Scholar
• AdorniMPZimettiFBillheimerJTThe roles of different pathways in the release of cholesterol from macrophagesJ Lipid Res2007482453246217761631
   PubMed Web of Science ®Google Scholar
• de la Llera-MoyaMDrazul-SchraderDAsztalosBFCuchelMRaderDJRothblatGHThe ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophagesArterioscler Thromb Vasc Biol20103079680120075420
   PubMed Web of Science ®Google Scholar
• FavariELeeMCalabresiLDepletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoproteinJ Biol Chem20042799930993614701812
   PubMed Web of Science ®Google Scholar
• RondaNFavariEBorghiMOImpaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosusAnn Rheum Dis20147360961523562986
   PubMed Web of Science ®Google Scholar
• DuongPTWeibelGLLund-KatzSRothblatGHPhillipsMCCharacterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-IJ Lipid Res2008491006101418252847
   PubMed Web of Science ®Google Scholar
• LeeJYParksJSATP-binding cassette transporter AI and its role in HDL formationCurr Opin Lipidol200516192515650559
   PubMed Web of Science ®Google Scholar
• KobayashiMGoudaKChisakiIOchiaiMItagakiSIsekiKRegulation mechanism of ABCA1 expression by statins in hepatocytesEur J Pharmacol201166291421554872
   PubMed Web of Science ®Google Scholar
• SongGLiuJZhaoZSimvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat dietLipids Health Dis201110821241519
   PubMed Web of Science ®Google Scholar
• GomaraschiMAdorniMPBanachMBerniniFFranceschiniGCalabresiLEffects of established hypolipidemic drugs on HDL concentration, subclass distribution, and functionHandb Exp Pharmacol201522459361525523003
   PubMedGoogle Scholar
• Bernelot MoensSJVerweijSLSchnitzlerJGRemnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humansArterioscler Thromb Vasc Biol20173796997528336558
   PubMed Web of Science ®Google Scholar
• PirilloACatapanoALBerberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studiesAtherosclerosis201524344946126520899
   PubMed Web of Science ®Google Scholar
• SahebkarASimental-MendiaLEGuerrero-RomeroFGolledgeJWattsGFEffect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trialsDiabetes Obes Metab2015171042105526183252
   PubMed Web of Science ®Google Scholar
• CameronJRanheimTKulsethMALerenTPBergeKEBerberine decreases PCSK9 expression in HepG2 cellsAtherosclerosis200820126627318355829
   PubMed Web of Science ®Google Scholar
• PelPChaeHSNhoekPKimYMChinYWChemical constituents with proprotein convertase subtilisin/kexin type 9 mRNA expression inhibitory activity from dried immature Morus alba fruitsJ Agric Food Chem2017655316532128649844
   PubMed Web of Science ®Google Scholar